Review of methods for measuring β‐cell function: Design considerations from the Restoring Insulin Secretion ( RISE ) Consortium
Open accessThe DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
The R estoring I nsulin S ecretion ( RISE ) study was initiated to evaluate interventions to slow or reverse the progression of β‐cell failure in type 2 diabetes ( T2D ). To design the RISE study, we undertook an evaluation of methods for measurement of β‐cell function and changes in β‐cell function in response to interventions. In the present paper, we review approaches for measurement of β‐cell function, focusing on methodologic and feasibility considerations. Methodologic considerations included: (1) the utility of each technique for evaluating key aspects of β‐cell function (first‐ and second‐phase insulin secretion, maximum insulin secretion, glucose sensitivity, incretin effects) and (2) tactics for incorporating a measurement of insulin sensitivity in order to adjust insulin secretion measures for insulin sensitivity appropriately. Of particular concern were the capacity to measure β‐cell function accurately in those with poor function, as is seen in established T2D , and the capacity of each method for demonstrating treatment‐induced changes in β‐cell function. Feasibility considerations included: staff burden, including time and required methodological expertise; participant burden, including time and number of study visits; and ease of standardizing methods across a multicentre consortium. After this evaluation, we selected a 2‐day measurement procedure, combining a 3‐hour 75‐g oral glucose tolerance test and a 2‐stage hyperglycaemic clamp procedure, augmented with arginine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985) · Diabetologia · doi:10.1007/bf00280883 · Cited by 31,502
β-Cell Deficit and Increased β-Cell Apoptosis in Humans With Type 2 Diabetes
Butler, A. E., Janson, J., Bonner-Weir, S., Ritzel, R., Rizza, R. A., & Butler, P. C. (2003) · Diabetes · doi:10.2337/diabetes.52.1.102 · Cited by 4,011
Katz, A., Nambi, S. S., Mather, K., Baron, A. D., Follmann, D. A., Sullivan, G., & Quon, M. J. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.7.6661 · Cited by 3,931
Self-citationGlycemic durability of rosiglitazone, metformin, or glyburide monotherapy
Kahn, S. E., Haffner, S. M., Heise, M. A., Herman, W. H., Holman, R. R., Jones, N. P., Kravitz, B. G., Lachin, J. M., O'Neill, M. C., Zinman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa066224 · Cited by 2,962
Self-citationBergman, R. N., Phillips, L. S., & Cobelli, C. (1981) · Journal of Clinical Investigation · doi:10.1172/jci110398 · Cited by 1,640
Kahn, S. E., Prigeon, R. L., McCulloch, D. K., Boyko, E. J., Bergman, R. N., Schwartz, M. W., Neifing, J. L., Ward, W. K., Beard, J. C., & Palmer, J. P. (1993) · Diabetes · doi:10.2337/diab.42.11.1663 · Cited by 1,405 · cited 2×
“The calculated line linking these factors, which exhibit a square hyperbolic relationship, is commonly expressed as the “disposition index” (DI; insulin sensitivity * first-phase insulin secretion [Figure 1]).(10,14) The need to incorporate a measurement of insulin sensitivity into assessments of β-cell responses is w…”
BackgroundSelf-citationBuchanan, T. A., Xiang, A. H., Peters, R. K., Kjos, S. L., Marroquin, A., Goico, J., Ochoa, C., Tan, S., Berkowitz, K., Hodis, H. N., et al. (2002) · Diabetes · doi:10.2337/diabetes.51.9.2796 · Cited by 1,339
Self-citationTwenty-four-hour profiles and pulsatile patterns of insulin secretion in normal and obese subjects.
Polonsky, K. S., Given, B. D., & Van Cauter, E. (1988) · Journal of Clinical Investigation · doi:10.1172/jci113339 · Cited by 763 · cited 1×
“It does this via a well-described pathway linking β-cell glucose uptake to changes in ADP/ATP ratios and ultimately to changes in membrane potassium conductance and movement of insulin granules, producing a pulsatile and oscillatory pattern of insulin secretion in health.(32,33) Non-glucose β-cell stimuli include incr…”
BackgroundPhillips, D. I. W., Clark, P. M., Hales, C. N., & Osmond, C. (1994) · Diabetic Medicine · doi:10.1111/j.1464-5491.1994.tb00273.x · Cited by 631 · cited 1×
“The early response can be evaluated simply as the rise in insulin/C-peptide above basal at any time interval up to 30 minutes after commencing glucose ingestion, or as the “insulinogenic index” (the increment above basal insulin/C-peptide divided by the increment in glucose in the same time interval).(71) The early in…”
BackgroundUtzschneider, K. M., Prigeon, R. L., Faulenbach, M. V., Tong, J., Carr, D. B., Boyko, E. J., Leonetti, D. L., McNeely, M. J., Fujimoto, W. Y., & Kahn, S. E. (2009) · Diabetes Care · doi:10.2337/dc08-1478 · Cited by 572
Self-citationAbdul-Ghani, M. A., Jenkinson, C. P., Richardson, D. K., Tripathy, D., & DeFronzo, R. A. (2006) · Diabetes · doi:10.2337/db05-1200 · Cited by 500
Diminished B cell secretory capacity in patients with noninsulin-dependent diabetes mellitus
Ward, W. K., Bolgiano, D. C., McKnight, B., Halter, J. B., & Porte, D. (1984) · Journal of Clinical Investigation · doi:10.1172/jci111542 · Cited by 483 · cited 1×
“Non-glucose β-cell stimuli include incretin hormones, acting through a cAMP system to potentiate the response to glucose,(34,35) and monobasic amino acids, fatty acids, and β-adrenergic agonists, which also act independent of the glucose-sensing systems but converge on the same insulin secretion pathways.(36) These fe…”
BackgroundGungor, N., Saad, R., Janosky, J., & Arslanian, S. (2004) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2003.09.045 · Cited by 457 · cited 1×
“in cross-sectional studies of healthy populations with NGT, but may be less reliably related in progressive dysglycaemia and diabetes.(27,83,97) Correlations with direct measures are weaker in longitudinal studies, even after accounting for increased variability of the measurements.”
BackgroundSelf-citationEhrmann, D. A., Sturis, J., Byrne, M. M., Karrison, T., Rosenfield, R. L., & Polonsky, K. S. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118064 · Cited by 426
Self-citationXiang, A. H., Peters, R. K., Kjos, S. L., Marroquin, A., Goico, J., Ochoa, C., Kawakubo, M., & Buchanan, T. A. (2006) · Diabetes · doi:10.2337/diabetes.55.02.06.db05-1066 · Cited by 402
Self-citationMather, K. J., Hunt, A. E., Steinberg, H. O., Paradisi, G., Hook, G., Katz, A., Quon, M. J., & Baron, A. D. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.11.7880 · Cited by 363 · cited 1×
“7).(29) The utility of surrogate indices for longitudinal”
BackgroundSelf-citationOral Glucose Tolerance Test Minimal Model Indexes of β-Cell Function and Insulin Sensitivity
Breda, E., Cavaghan, M. K., Toffolo, G., Polonsky, K. S., & Cobelli, C. (2001) · Diabetes · doi:10.2337/diabetes.50.1.150 · Cited by 320
Toffolo, G., Bergman, R. N., Finegood, D. T., Bowden, C. R., & Cobelli, C. (1980) · Diabetes · doi:10.2337/diab.29.12.979 · Cited by 292 · cited 2×
“The minimal model of glucose kinetics developed by Toffolo et al.(23) and Bergman et al.”
MethodWard, W. K., LaCava, E. C., Paquette, T. L., Beard, J. C., Wallum, B. J., & Porte, D. (1987) · Diabetologia · doi:10.1007/bf00296991 · Cited by 275 · cited 10×
“Minimal model methodologies have been developed that allow insulin response and insulin sensitivity to be simultaneously assessed with a multiple-sample, extended OGTT.79–81 These models have been used to assess β-cell function during physiological testing in subjects with NGT, prediabetes and T2D.”
BackgroundInfluentialKahn, S. E., Lachin, J. M., Zinman, B., Haffner, S. M., Aftring, R. P., Paul, G., Kravitz, B. G., Herman, W. H., Viberti, G., Holman, R. R., et al. (2011) · Diabetes · doi:10.2337/db10-1392 · Cited by 249
Self-citationCobelli, C., Dalla Man, C., Toffolo, G., Basu, R., Vella, A., & Rizza, R. (2014) · Diabetes · doi:10.2337/db13-1198 · Cited by 216
Cavaghan, M. K., Ehrmann, D. A., Byrne, M. M., & Polonsky, K. S. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119562 · Cited by 216
Self-citationPathophysiology of insulin secretion in non-insulin-dependent diabetes mellitus
Ward, W. K., Beard, J. C., Halter, J. B., Pfeifer, M. A., & Porte, D. (1984) · Diabetes Care · doi:10.2337/diacare.7.5.491 · Cited by 215
Vilsbøll, T., Brock, B., Perrild, H., Levin, K., Lervang, H. ‐., Kølendorf, K., Krarup, T., Schmitz, O., Zdravkovic, M., Le‐Thi, T., et al. (2008) · Diabetic Medicine · doi:10.1111/j.1464-5491.2007.02333.x · Cited by 213
Modeling Phasic Insulin Release
Nesher, R., & Cerasi, E. (2002) · Diabetes · doi:10.2337/diabetes.51.2007.s53 · Cited by 179
Elahi, D. (1996) · Diabetes Care · doi:10.2337/diacare.19.3.278 · Cited by 168 · cited 2×
“repeatable stimulus to insulin/C-peptide secretion and clear separation of first- and second-phase responses to intravenous glucose (Figure 2).(21,22)”
BackgroundDisproportionately Elevated Proinsulin in Pima Indians with Noninsulin-Dependent Diabetes Mellitus*
SAAD, M. F., KAHN, S. E., NELSON, R. G., PETTITT, D. J., KNOWLER, W. C., SCHWARTZ, M. W., KOWALYK, S., BENNETT, P. H., & PORTE, D. (1990) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-70-5-1247 · Cited by 167
Self-citationProinsulin as a marker for the development of NIDDM in Japanese-American men
Kahn, S. E., Leonetti, D. L., Prigeon, R. L., Boyko, E. J., Bergstrom, R. W., & Fujimoto, W. Y. (1995) · Diabetes · doi:10.2337/diabetes.44.2.173 · Cited by 138
Self-citationO'Meara, N. M., Sturis, J., Van Cauter, E., & Polonsky, K. S. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116560 · Cited by 132 · cited 1×
“It does this via a well-described pathway linking β-cell glucose uptake to changes in ADP/ATP ratios and ultimately to changes in membrane potassium conductance and movement of insulin granules, producing a pulsatile and oscillatory pattern of insulin secretion in health.(32,33) Non-glucose β-cell stimuli include incr…”
BackgroundCali, A. M. G., Man, C. D., Cobelli, C., Dziura, J., Seyal, A., Shaw, M., Allen, K., Chen, S., & Caprio, S. (2009) · Diabetes Care · doi:10.2337/dc08-1274 · Cited by 125
Self-citationToffolo, G., Breda, E., Cavaghan, M. K., Ehrmann, D. A., Polonsky, K. S., & Cobelli, C. (2001) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.2001.280.1.e2 · Cited by 112 · cited 3×
“the up-/downgraded procedure, or to perform a hyperinsulinaemic clamp on a separate day.(59) Here again, there was a concern that modelling for individuals with poor β-cell function and poor insulin”
MethodInfluentialSelf-citationBacha, F., Gungor, N., Lee, S., & Arslanian, S. A. (2013) · Pediatric Diabetes · doi:10.1111/j.1399-5448.2012.00915.x · Cited by 106
Self-citationIn Vivo Insulin Sensitivity and Secretion in Obese Youth
Bacha, F., Gungor, N., Lee, S., & Arslanian, S. A. (2009) · Diabetes Care · doi:10.2337/dc08-1030 · Cited by 90
Self-citationElder, D. A., Prigeon, R. L., Wadwa, R. P., Dolan, L. M., & D’Alessio, D. A. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-0853 · Cited by 78
Characterization of GLP-1 Effects on β-Cell Function After Meal Ingestion in Humans
Ahrén, B., Holst, J. J., & Mari, A. (2003) · Diabetes Care · doi:10.2337/diacare.26.10.2860 · Cited by 72 · cited 1×
“Recently, combinations of glucose with glucagon-like peptide-1 (GLP1) or GLP-1 mimetics have also been used.(11,34,35) It is not clear whether these combination approaches offer an advantage in cost,”
BackgroundDalla Man, C., Micheletto, F., Sathananthan, M., Vella, A., & Cobelli, C. (2016) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2015.0146 · Cited by 24 · cited 1×
“Recently, combinations of glucose with glucagon-like peptide-1 (GLP1) or GLP-1 mimetics have also been used.(11,34,35) It is not clear whether these combination approaches offer an advantage in cost,”
Background
Cited by
The RISE Consortium, Nadeau, K. J., Hannon, T. S., Edelstein, S. L., Arslanian, S. A., Caprio, S., Leschek, E. W., Zeitler, P. S., Buchanan, T. A., Ehrmann, D. A., et al. (2018) · Diabetes Care · doi:10.2337/dc18-0787 · Cited by 176
Self-citationThe RISE Consortium, Ehrmann, D. A., Temple, K. A., Rue, A., Barengolts, E., Mokhlesi, B., Van Cauter, E., Sam, S., Miller, M. A., Kahn, S. E., et al. (2019) · Diabetes Care · doi:10.2337/dc19-0556 · Cited by 73
Self-citationAnyiam, O., Phillips, B., Quinn, K., Wilkinson, D., Smith, K., Atherton, P., & Idris, I. (2024) · Clinical Nutrition · doi:10.1016/j.clnu.2024.06.034 · Cited by 40
Xiang, A. H., Trigo, E., Martinez, M., Katkhouda, N., Beale, E., Wang, X., Wu, J., Chow, T., Montgomery, C., Nayak, K. S., et al. (2018) · Diabetes Care · doi:10.2337/dc18-1662 · Cited by 37
“Study Protocol The rationale and methods for the BetaFat study have been described in detail (16,18).”
MethodSelf-citation
Metadata
- Authors
- Hannon, T. S., Kahn, S. E., Utzschneider, K. M., Buchanan, T. A., Nadeau, K. J., Zeitler, P. S., Ehrmann, D. A., Arslanian, S. A., Caprio, S., Edelstein, S. L., Savage, P. J., Mather, K. J., & for the RISE Consortium
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2017-06-22
- Volume
- 20
- Issue
- 1
- Pages
- 14-24
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W2613617001
- Cited by
- 87
- References
- 36
- FWCI
- 6.32
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.